CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉ STUDIIClinical Study Agreement • June 17th, 2022
Contract Type FiledJune 17th, 2022This Clinical Study Agreement (“Agreement”) is entered into as of the date of last signature hereto (the “Effective Date”) by and between Fakultní nemocnice v Motole, with offices at V Úvalu 84, 15006 Prague 5, Czech Republic, Company ID no. 00064203, Tax ID no. CZ00064203, represented by JUDr. Ing. Miloslav Ludvík, MBA, director, based on appointment dated 27.4.2000 (the “Institution”) and Merrimack Pharmaceuticals, Inc., a Delaware corporation with offices at 1 Kendall Square, suite B7201, Cambridge, MA 02139 (together with its affiliates and subsidiaries, the “Sponsor”), in connection with a clinical trial conducted pursuant to Protocol MM-302-02-02- 03, “A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2- Positive Breast Cancer” (the “Protocol”) (the “Study”). The Study will be conducted under the immediate supervision o